Vaidya Govindarajan

Vaidya Govindarajan

Auto-generated profile, based on publicly available information

Vaidya Govindarajan

Neurological Surgery, University of Miami MILLER School of Medicine, Miami, Florida, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Ashish H. ShahAshish H. Shah
Ashish H. Shah
SRSarah Renae Rivas
Sarah Renae Rivas
TDTara T. Doucet-O'Hare
Tara T. Doucet-O'Hare
VGVaidya Govindarajan
Vaidya Govindarajan
CDCatherine DeMarino
Catherine DeMarino
ANAvindra Nath
Avindra Nath
Human endogenous retroviruses (HERVs) are ancestral viral relics that constitute nearly 8% of the human genome. Although normally silenced, the most recently integrated provirus HERV-K (HML-2) can be reactivated in certain cancers. Here, we report pathological expression of HML-2 in malignant gliomas in both cerebrospinal fluid and tumor tissue that was associated with a cancer stem cell phenotype and poor outcomes. Using single-cell RNA-Seq, we identified glioblastoma cellular populations with elevated HML-2 transcripts in neural progenitor–like cells (NPC-like) that drive cellular plasticity. Using CRISPR interference, we demonstrate that HML-2 critically maintained glioblastoma stemness and tumorigenesis in both glioblastoma neurospheres and intracranial orthotopic murine models. Additionally, we demonstrate that HML-2 critically regulated embryonic stem cell programs in NPC-derived astroglia and altered their 3D cellular morphology by activating the nuclear transcription factor OCT4, which binds to an HML-2–specific long-terminal repeat (LTR5Hs). Moreover, we discovered that some glioblastoma cells formed immature retroviral virions, and inhibiting HML-2 expression with antiretroviral drugs reduced reverse transcriptase activity in the extracellular compartment, tumor viability, and pluripotency. Our results suggest that HML-2 fundamentally contributes to the glioblastoma stem cell niche. Because persistence of glioblastoma stem cells is considered responsible for treatment resistance and recurrence, HML-2 may serve as a unique therapeutic target.

1 August 2021 in World Neurosurgery
Verified
Journal Article
Closed access
VGVaidya Govindarajan
Vaidya Govindarajan
ELEvan M. Luther
Evan M. Luther
AMAlexis A. Morell
Alexis A. Morell
JBJoshua D. Burks
Joshua D. Burks
HKHunter King
Hunter King
Michael E. IvanMichael E. Ivan
Michael E. Ivan

18 March 2022 in World Neurosurgery
Verified
Journal Article
Closed access
VGVaidya Govindarajan
Vaidya Govindarajan
Ashish H. ShahAshish H. Shah
Ashish H. Shah
LDLong Di
Long Di
SRSarah Rivas
Sarah Rivas
RSRobert K Suter
Robert K Suter
MFMacarena De La Fuente
Macarena De La Fuente

17 March 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DSDeepa Seetharam
Deepa Seetharam
JCJay Chandar
Jay Chandar
CRChristian Ramsoomair
Christian Ramsoomair
JDJelisah F. Desgraves
Jelisah F. Desgraves
AMAlexandra Alvarado Medina
Alexandra Alvarado Medina
Ashish H. ShahAshish H. Shah
Ashish H. Shah
Viral mimicry refers to the activation of innate antiviral immune responses due to the induction of endogenous retroelements (REs). Viral mimicry augments antitumor immune responses and sensitizes solid tumors to immunotherapy. Here, we found that targeting what we believe to be a novel, master epigenetic regulator, Zinc Finger Protein 638 (ZNF638), induces viral mimicry in glioblastoma (GBM) preclinical models and potentiates immune checkpoint inhibition (ICI). ZNF638 recruits the HUSH complex, which precipitates repressive H3K9me3 marks on endogenous REs. In GBM, ZNF638 is associated with marked locoregional immunosuppressive transcriptional signatures, reduced endogenous RE expression, and poor immune cell infiltration. Targeting ZNF638 decreased H3K9 trimethylation, increased REs, and activated intracellular dsRNA signaling cascades. Furthermore, ZNF638 knockdown upregulated antiviral immune programs and significantly increased PD-L1 immune checkpoint expression in diverse GBM models. Importantly, targeting ZNF638 sensitized mice to ICI in syngeneic murine orthotopic models through innate IFN signaling. This response was recapitulated in recurrent GBM (rGBM) samples with radiographic responses to checkpoint inhibition with widely increased expression of dsRNA, PD-L1, and perivascular CD8 cell infiltration, suggesting that dsRNA signaling may mediate response to immunotherapy. Finally, low ZNF638 expression was a biomarker of clinical response to ICI and improved survival in patients with rGBM and patients with melanoma. Our findings suggest that ZNF638 could serve as a target to potentiate immunotherapy in gliomas.

31 December 2023 in Neurospine
Verified
Journal Article
Open access
PDF file
KBKatherine M. Berry
Katherine M. Berry
VGVaidya Govindarajan
Vaidya Govindarajan
CBConnor Berger
Connor Berger
KMKRISNA SCARLETT MADDY
KRISNA SCARLETT MADDY
RRRoberto J. Perez Roman
Roberto J. Perez Roman
UMUniversity of Miami Miller School of Medicine
University of Miami Miller School of Medicine
Objective: High body mass index is a well-established modifiable comorbidity that is known to increase postoperative complications in all types of surgery, including spine surgery. Obesity is increasing in prevalence amongst the general population. As this growing population of obese patients ages, understanding how they faire undergoing cervical disc arthroplasty (CDA) is important for providing safe and effective evidence-based care for cervical degenerative pathology.Methods: Our study used the Healthcare Cost and Utilization Project’s National Inpatient Sample to assess patients undergoing CDA comparing patient characteristics and outcomes in nonobese patients to obese patients from 2004 to 2014.Results: Our study found a significant increase in the overall utilization of CDA as a treatment modality (p = 0.012) and a statistically significant increase in obese patients undergoing CDA (p < 0.0001) from 2004 to 2014. Obesity was identified as an independent risk factor associated with increased rates of inpatient neurologic complications (odds ratio [OR], 6.99; p = 0.03), pulmonary embolus (OR, 5.41; p = 0.05), and wound infection (OR, 6.97; p < 0.001) in patients undergoing CDA from 2004 to 2014.Conclusion: In patients undergoing CDA, from 2004 to 2014, obesity was identified as an independent risk factor with significantly increased rates of inpatient neurologic complications, pulmonary embolus and wound infection. Large prospective trials are needed to validate these findings.

1 July 2021 in Cerebrovascular Diseases
Verified
Journal Article
Open access
PDF file
VGVaidya Govindarajan
Vaidya Govindarajan
JBJoshua D. Burks
Joshua D. Burks
ELEvan M. Luther
Evan M. Luther
JTJohn W. Thompson
John W. Thompson
RSRobert M. Starke
Robert M. Starke
Background: Arteriovenous malformations (AVMs) of the brain and face present unique challenges for clinicians. Cerebral AVMs may induce hemorrhage or form aneurysms, while facial AVMs can cause significant disfigurement and pain. Moreover, facial AVMs often draw blood supply from arteries providing critical blood flow to other important structures of the head which may make them impossible to treat curatively. Medical adjuvants may be an important consideration in the management of these patients. Summary: We conducted a systematic review of the literature to identify other instances of molecular target of rapamycin (mTOR) inhibitors used as medical adjuvants for the treatment of cranial and facial AVMs. We also present 2 cases from our own institution where patients were treated with partial embolization, followed by adjuvant therapy with rapamycin. After screening a total of 75 articles, 7 were identified which described use of rapamycin in the treatment of inoperable cranial or facial AVM. In total, 21 cases were reviewed. The median treatment duration was 12 months (3–24.5 months), and the highest recorded dose was 3.5 mg/m2. 76.2% of patients demonstrated at least a partial response to rapamycin therapy. In 2 patients treated at our institution, symptomatic and radiographic improvement were noted 6 months after initiation of therapy. Key Messages: Early results have been encouraging in a small number of patients with inoperable AVM of the head and face treated with mTOR inhibitors. Further study of medical adjuvants such as rapamycin may be worthwhile.